- Home
- FBYD vs CRDL Comparison
FBYD vs CRDL Comparison
Compare FBYD & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- CRDL
- Stock Information
- Founded
- FBYD 2021
- CRDL 2017
- Country
- FBYD United States
- CRDL Canada
- Employees
- FBYD N/A
- CRDL N/A
- Industry
- FBYD
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBYD
- CRDL Health Care
- Exchange
- FBYD Nasdaq
- CRDL Nasdaq
- Market Cap
- FBYD 120.8M
- CRDL 125.7M
- IPO Year
- FBYD N/A
- CRDL N/A
- Fundamental
- Price
- FBYD $9.10
- CRDL $1.41
- Analyst Decision
- FBYD
- CRDL Strong Buy
- Analyst Count
- FBYD 0
- CRDL 3
- Target Price
- FBYD N/A
- CRDL $9.00
- AVG Volume (30 Days)
- FBYD 29.0K
- CRDL 416.4K
- Earning Date
- FBYD 02-01-2025
- CRDL 11-14-2024
- Dividend Yield
- FBYD N/A
- CRDL N/A
- EPS Growth
- FBYD N/A
- CRDL N/A
- EPS
- FBYD N/A
- CRDL N/A
- Revenue
- FBYD $7,530,000.00
- CRDL N/A
- Revenue This Year
- FBYD N/A
- CRDL N/A
- Revenue Next Year
- FBYD N/A
- CRDL N/A
- P/E Ratio
- FBYD N/A
- CRDL N/A
- Revenue Growth
- FBYD N/A
- CRDL N/A
- 52 Week Low
- FBYD $5.85
- CRDL $0.79
- 52 Week High
- FBYD $13.25
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- FBYD 53.79
- CRDL 36.64
- Support Level
- FBYD $8.51
- CRDL $1.27
- Resistance Level
- FBYD $9.76
- CRDL $1.67
- Average True Range (ATR)
- FBYD 0.88
- CRDL 0.09
- MACD
- FBYD 0.11
- CRDL 0.00
- Stochastic Oscillator
- FBYD 27.72
- CRDL 35.00
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.